Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience.

Takefumi Yazawa, Tomohide Hori, Hidekazu Yamamoto, Hideki Harada, Michihiro Yamamoto, Masahiro Yamada, Masaki Tani, Asahi Sato, Yasuyuki Kamada, Ryotaro Tani, Ryuhei Aoyama, Yudai Sasaki, Masazumi Zaima
{"title":"Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience.","authors":"Takefumi Yazawa, Tomohide Hori, Hidekazu Yamamoto, Hideki Harada, Michihiro Yamamoto, Masahiro Yamada, Masaki Tani, Asahi Sato, Yasuyuki Kamada, Ryotaro Tani, Ryuhei Aoyama, Yudai Sasaki, Masazumi Zaima","doi":"10.4292/wjgpt.v11.i5.110","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Advanced gastric cancer (GC) with liver metastasis is often characterized by multiple and bilobular metastases and may also be associated with extrahepatic metastatic lesions. Hence, many physicians consider that radical surgeries are contraindicated for liver metastases from GC (LMGC). According to the 2017 Japanese treatment guideline for GC, a smaller number of liver metastases without unresectable factors may be an indication for liver resection (LR) with curability. The actual 5-year overall survival (OS) rate ranges from 0 to 0.37.</p><p><strong>Aim: </strong>To present the institutional indications for LR for LMGC and identify important factors for prognostic outcomes.</p><p><strong>Methods: </strong>In total, 30 patients underwent LR for LMGC during a 14-year period, and we evaluated the clinical, surgical, and oncological findings. In all patients, radical surgery with intentional lymphadenectomy was performed for the primary GC. The median follow-up duration after the initial LR was 33.7 mo, and three patients with no recurrence died of causes unrelated to the LMGC. The OS and recurrence-free survival rates after the initial LR were assessed.</p><p><strong>Results: </strong>Seventeen patients had metachronous LMGC. The initial LR achieved curability in 29 patients. Perioperative chemotherapy was introduced in 23 patients. The median greatest LMGC dimension was 30 mm, and the median number of LMGC was two. Twenty-two patients had unilobular LMGC. The 5-year OS and recurrence-free survival rates were 0.48 and 0.28, respectively. The median survival duration and recurrence-free duration after the initial LR were 16.8 and 8.6 mo, respectively. Twenty-one patients developed recurrence after the initial LR. Additional surgeries for recurrence were performed in nine patients, and these surgeries clearly prolonged the patients' survival. Pathological serosal invasion was an independent predictor of a poor prognostic outcome after the initial LR. Aggressive LR may be indicated for carefully selected patients with LMGC.</p><p><strong>Conclusion: </strong>Our results of LR for LMGC seem acceptable. Additional surgeries for recurrence after the initial LR might prolong OS. Pathological serosal invasion is important for poor prognostic outcomes.</p>","PeriodicalId":23755,"journal":{"name":"World Journal of Gastrointestinal Pharmacology and Therapeutics","volume":"11 5","pages":"110-122"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/75/WJGPT-11-110.PMC7667407.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4292/wjgpt.v11.i5.110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Advanced gastric cancer (GC) with liver metastasis is often characterized by multiple and bilobular metastases and may also be associated with extrahepatic metastatic lesions. Hence, many physicians consider that radical surgeries are contraindicated for liver metastases from GC (LMGC). According to the 2017 Japanese treatment guideline for GC, a smaller number of liver metastases without unresectable factors may be an indication for liver resection (LR) with curability. The actual 5-year overall survival (OS) rate ranges from 0 to 0.37.

Aim: To present the institutional indications for LR for LMGC and identify important factors for prognostic outcomes.

Methods: In total, 30 patients underwent LR for LMGC during a 14-year period, and we evaluated the clinical, surgical, and oncological findings. In all patients, radical surgery with intentional lymphadenectomy was performed for the primary GC. The median follow-up duration after the initial LR was 33.7 mo, and three patients with no recurrence died of causes unrelated to the LMGC. The OS and recurrence-free survival rates after the initial LR were assessed.

Results: Seventeen patients had metachronous LMGC. The initial LR achieved curability in 29 patients. Perioperative chemotherapy was introduced in 23 patients. The median greatest LMGC dimension was 30 mm, and the median number of LMGC was two. Twenty-two patients had unilobular LMGC. The 5-year OS and recurrence-free survival rates were 0.48 and 0.28, respectively. The median survival duration and recurrence-free duration after the initial LR were 16.8 and 8.6 mo, respectively. Twenty-one patients developed recurrence after the initial LR. Additional surgeries for recurrence were performed in nine patients, and these surgeries clearly prolonged the patients' survival. Pathological serosal invasion was an independent predictor of a poor prognostic outcome after the initial LR. Aggressive LR may be indicated for carefully selected patients with LMGC.

Conclusion: Our results of LR for LMGC seem acceptable. Additional surgeries for recurrence after the initial LR might prolong OS. Pathological serosal invasion is important for poor prognostic outcomes.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胃癌肝转移是否为积极手术切除的禁忌症?14 年的单中心经验。
背景:伴有肝转移的晚期胃癌(GC)通常以多发性和双叶转移为特征,也可能伴有肝外转移病灶。因此,许多医生认为根治性手术是胃癌肝转移(LMGC)的禁忌症。根据2017年日本GC治疗指南,较少数量的肝转移灶且无不可切除因素,可作为肝切除术(LR)的适应症,且具有治愈性。实际5年总生存率(OS)从0到0.37不等。目的:介绍LMGC LR的机构适应症,并确定预后结果的重要因素:方法:14年间,共有30名患者接受了LMGC的LR手术,我们对其临床、手术和肿瘤学结果进行了评估。所有患者均接受了原发 GC 的根治术和有意的淋巴结切除术。初次淋巴结清扫术后的中位随访时间为 33.7 个月,其中有 3 例未复发的患者死于与 LMGC 无关的原因。对初次淋巴结转移后的OS和无复发生存率进行了评估:结果:17名患者患有晚期LMGC。结果:17 名患者患有并发 LMGC,29 名患者的初次 LR 达到治愈。23名患者接受了围手术期化疗。LMGC最大尺寸中位数为30毫米,LMGC数量中位数为2个。22例患者为单叶LMGC。5年OS和无复发生存率分别为0.48和0.28。初次 LR 后的中位生存期和无复发生存期分别为 16.8 个月和 8.6 个月。21 名患者在初次 LR 后复发。9名患者因复发接受了额外手术,这些手术明显延长了患者的生存期。病理血清学侵犯是初次 LR 后预后不良的独立预测因素。经过仔细筛选的LMGC患者可能需要进行积极的LR手术:结论:我们对LMGC的LR结果似乎是可以接受的。结论:我们对LMGC进行LR治疗的结果似乎是可以接受的,在首次LR后对复发进行额外手术可能会延长OS。病理血清学侵犯是预后不良的重要原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Effectiveness of an amino acid beverage formulation in diarrhea-predominant irritable bowel syndrome: A pragmatic real-world study Hepatitis C virus treatment with glecaprevir and pibrentasvir in patients co-prescribed carbamazepine: Three case reports. Update on the strategy for intravenous fluid treatment in acute pancreatitis. Cinnamic acid regulates the intestinal microbiome and short-chain fatty acids to treat slow transit constipation. "Timing of percutaneous endoscopic gastrostomy tube placement in post-stroke patients does not impact mortality, complications, or outcomes": Commentary.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1